1. Home
  2. PRTC vs NVTS Comparison

PRTC vs NVTS Comparison

Compare PRTC & NVTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • NVTS
  • Stock Information
  • Founded
  • PRTC 2015
  • NVTS 2014
  • Country
  • PRTC United States
  • NVTS United States
  • Employees
  • PRTC N/A
  • NVTS N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • NVTS Semiconductors
  • Sector
  • PRTC Health Care
  • NVTS Technology
  • Exchange
  • PRTC Nasdaq
  • NVTS Nasdaq
  • Market Cap
  • PRTC 432.3M
  • NVTS 383.0M
  • IPO Year
  • PRTC N/A
  • NVTS N/A
  • Fundamental
  • Price
  • PRTC $18.50
  • NVTS $5.10
  • Analyst Decision
  • PRTC Buy
  • NVTS Strong Buy
  • Analyst Count
  • PRTC 1
  • NVTS 6
  • Target Price
  • PRTC $45.00
  • NVTS $3.79
  • AVG Volume (30 Days)
  • PRTC 3.2K
  • NVTS 50.6M
  • Earning Date
  • PRTC 04-30-2025
  • NVTS 05-05-2025
  • Dividend Yield
  • PRTC N/A
  • NVTS N/A
  • EPS Growth
  • PRTC N/A
  • NVTS N/A
  • EPS
  • PRTC 0.21
  • NVTS N/A
  • Revenue
  • PRTC $4,828,000.00
  • NVTS $74,145,000.00
  • Revenue This Year
  • PRTC $35.98
  • NVTS N/A
  • Revenue Next Year
  • PRTC $115.38
  • NVTS $50.76
  • P/E Ratio
  • PRTC $8.24
  • NVTS N/A
  • Revenue Growth
  • PRTC 44.98
  • NVTS N/A
  • 52 Week Low
  • PRTC $13.30
  • NVTS $1.52
  • 52 Week High
  • PRTC $32.98
  • NVTS $7.53
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 58.17
  • NVTS 66.09
  • Support Level
  • PRTC $17.80
  • NVTS $1.88
  • Resistance Level
  • PRTC $19.17
  • NVTS $7.53
  • Average True Range (ATR)
  • PRTC 0.48
  • NVTS 0.65
  • MACD
  • PRTC 0.13
  • NVTS 0.37
  • Stochastic Oscillator
  • PRTC 74.72
  • NVTS 57.00

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.

Share on Social Networks: